Farnesyl transferase inhibitor can help patients at high-risk for developing AML

ASH news tips from M. D. Anderson Cancer Center

The University of Texas M. D. Anderson Cancer Center offers these news items presented at the annual meeting of the American Society of Hematology (ASH). An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

The drug R115777 (Zarnestra) (tipifarnib) produced responses that ranged from complete responses to improvement in blood counts in about one-third of 82 patients treated at seven different hospitals in the United States, Canada, and Europe, says the study’s lead investigator, Razelle Kurzrock, M.D., a professor in the Department of Experimental Therapeutics at M. D. Anderson Cancer Center.

That level of response, as well as side effects that are well tolerated, can be a boon to the mostly elderly patients who develop the syndrome, Kurzrock says. “It is one more drug that can be tried to help improve blood counts and prevent leukemia development in these patients,” she says. At the time the study began, there was no approved therapy to treat MDS, but recently, the FDA approved use of azacytidine (Vidaza), which is a chemotherapy drug administered subcutaneously. Zarnestra helps about as many patients as Vidaza, “but for diseases like this, you need more than one drug because the syndrome is made up of numerous subtypes,” Kurzrock says. “If one drug doesn’t help, then the other might; or they could potentially be used together.”

Zarnestra belongs to a group of drugs known as farnesyl transferase inhibitors, which block enzymes needed for the activation of cancer-promoting proteins. While the drug was initially believed to act primarily on the ras gene, which is mutated in about 25 percent of MDS patients, recent studies including this one demonstrate that patients whose ras gene is normal can benefit, Kurzrock says. “It has become apparent that Zarnestra regulates other important cancer genes, although we don’t know which ones they are.”

Media Contact

Nancy Jensen EurekAlert!

More Information:

http://www.mdanderson.org

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Security vulnerability in browser interface

… allows computer access via graphics card. Researchers at Graz University of Technology were successful with three different side-channel attacks on graphics cards via the WebGPU browser interface. The attacks…

A closer look at mechanochemistry

Ferdi Schüth and his team at the Max Planck Institut für Kohlenforschung in Mülheim/Germany have been studying the phenomena of mechanochemistry for several years. But what actually happens at the…

Severe Vulnerabilities Discovered in Software to Protect Internet Routing

A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key…

Partners & Sponsors